Huahaipharm: Huaotai has received FDA approval to conduct Phase I clinical trials of injectable HB0043 in the United States
I'm PortAI, I can summarize articles.
Huahaipharm's subsidiary Huaotai has received FDA approval to conduct Phase I clinical trials of injectable HB0043 in the United States. HB0043 is a bispecific antibody targeting IL-17A and IL-36R, with high binding and blocking activity, aimed at treating various autoimmune diseases. Compared to monoclonal antibodies, HB0043 demonstrates stronger performance in suppressing inflammation and fibrotic responses, potentially providing new treatment ideas for immune-mediated inflammatory skin diseases and fibrotic diseases
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments